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Abstract
Background: Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2
diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin
secretion and biosynthesis, suppressing glucagon secretion, and delaying gastric emptying and promoting satiety.
This systematic review aims to provide evidence on the clinical effectiveness of the GLP-1 agonists in patients not
achieving satisfactory glycaemic control with one or more oral glucose lowering drugs.
Methods: MEDLINE, EMBASE, the Cochrane Library and Web of Science were searched to find the relevant papers.
We identified 28 randomised controlled trials comparing GLP-1 analogues with placebo, other glucose-lowering
agents, or another GLP-1 analogue, in patients with type 2 diabetes with inadequate control on a single oral agent,
or on dual therapy. Primary outcomes included HbA1c, weight change and adverse events.
Results: Studies were mostly of short duration, usually 26 weeks. All GLP-1 agonists reduced HbA1c by about 1%
compared to placebo. Exenatide twice daily and insulin gave similar reductions in HbA1c, but exenatide 2 mg
once weekly and liraglutide 1.8 mg daily reduced it by 0.20% and 0.30% respectively more than glargine.
Liraglutide 1.2 mg daily reduced HbA1c by 0.34% more than sitagliptin 100 mg daily. Exenatide and liraglutide
gave similar improvements in HbA1c to sulphonylureas. Exenatide 2 mg weekly and liraglutide 1.8 mg daily
reduced HbA1c by more than exenatide 10 μg twice daily and sitagliptin 100 mg daily. Exenatide 2 mg weekly
reduced HbA1c by 0.3% more than pioglitazone 45 mg daily.
Exenatide and liraglutide resulted in greater weight loss (from 2.3 to 5.5 kg) than active comparators. This was not
due simply to nausea. Hypoglycaemia was uncommon, except when combined with a sulphonylurea. The com-
monest adverse events with all GLP-1 agonists were initial nausea and vomiting. The GLP-1 agonists have some
effect on beta-cell function, but this is not sustained after the drug is stopped.
Conclusions: GLP-1 agonists are effective in improving glycaemic control and promoting weight loss.
Background
Type 2 diabetes mellitus
The primary aim of treatments for type 2 diabetes is to
control blood glucose and reduce the development of
diabetes-associated secondary complications [1]. Over
time, persistently elevated levels of plasma glucose
(hyperglycaemia) lead to various microvascular (retino-
pathy, nephropathy and neuropathy) and macrovascular
(cardiovascular diseases) complications. The risk of
developing such complications is strongly associated
with the period of exposure to hyperglycaemia [2].
Initially people with type 2 diabetes should be advised
on lifestyle changes (weight loss, increasing physical
activity, diet) and offered ongoing patient education. If
the lifestyle changes fail to control blood glucose then
an oral glucose-lowering agent is given, usually metfor-
min [3]. If metformin is contraindicated or not tolerated
then sulphonylureas are considered. Type 2 diabetes is
usually a progressive disease, with loss of beta cell capa-
city [4]. Once one oral glucose-lowering agent is insuffi-
cient to provide adequate glycaemic control a second is
added (usually a sulphonylurea) to the initial metformin.
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effects, such as weight gain and hypoglycaemia, which
might affect patient compliance and therefore glycaemic
control. The American Diabetes Association (ADA) and
the European Association for the Study of Diabetes
(EASD) suggest that an HbA1c level of >7% indicates
inadequate control [5].
At present, when people with type 2 diabetes have
poor control on a combination of oral agents, the usual
next step is to start insulin treatment [3], which often
causes weight gain and hypoglycaemia, and often does
not achieve good control [6].
Therefore existing treatments for these patients are
unsatisfactory, and many patients do not have good gly-
caemic control, which will increase the risk of complica-
tions. New and better treatments are required.
The glucagon-like peptide 1 analogues
GLP-1 analogues are a new class of glucose lowering
drugs, given by injection, that mimic the action of an
endogenous gastrointestinal hormone GLP-1, an incretin
hormone that is released into the circulation in response
to food. It regulates glucose levels by stimulating glucose
dependent insulin secretion and biosynthesis, and by
suppressing glucagon secretion, delaying gastric empty-
ing and promoting satiety [7,8].
The action of the GLP-1 analogues is glucose-depen-
dent i.e. the higher the plasma glucose level, the greater
the effect of GLP-1 agonists on insulin secretion, with
the greatest effect in hyperglycaemic conditions, and lit-
tle or no effect when the blood glucose concentration is
less than 3.6 mmol/L (65 mg/dL). This should reduce
the occurrence of hypoglycaemia. The GLP-1 analogues
have also been reported to produce weight loss in
patients with type 2 diabetes [3,9-12].
T h e r ei ss o m ee v i d e n c ef r o ma n i m a lm o d e l st h a tt h e
GLP-1 analogues increases pancreatic islet beta-cell mass
[13] and reduce beta-cell apoptosis [14,15]. If GLP-1 ana-
logues do enhance beta-cell survival and stimulate beta-
cell growth in individuals with type 2 diabetes, they may
provide a means to preserve or restore functional beta-
cell mass. This would be an important advance.
There are now at least six GLP-1 analogues: exenatide
(Byetta, Lilly/Amylin) and liraglutide (Victoza, Novo
Nordisk), that have reached the market, while albiglutide
(GlaxoSmithKline) and taspoglutide (Ipsen and Roche)
have been the subject of published trials. Others, includ-
ing lixisenatide (sanofi-aventis) and LY2189265 (Lilly)
are in the pipeline.
In the UK, the NICE guideline suggests that the GLP-
1 analogues should be used as third line agents [3]. In
the USA, they are often used as second-line.
There have been several good quality reviews of GLP-
1 agonists [9-12] but most have included all trials,
some of which are not relevant to clinical practice (e.g.
patients who have not first failed metformin or a sul-
phonylurea or both), and none include trials published
up to July 2010. This review aims to investigate the
effectiveness of GLP-1 analogues in patients with type 2
diabetes mellitus who are not achieving satisfactory gly-
caemic control with one or more oral glucose lowering
drugs.
Methods
Searching
The electronic databases MEDLINE (1996 to July 2010),
EMBASE (1998 to July 2010), the Cochrane Library
(July 2010) and Web of Science (1980 to July 2010)
were searched for relevant papers.
The following Medline search strategy (Ovid) was
adapted for use with the other databases:
1. exp Glucagon-Like Peptides/
2. (glucagon like peptide* or GLP-1).tw.
3. (exenatide or liraglutide or albiglutide or taspoglu-
tide or lixisenatide).tw.
4. randomized controlled trial.pt.
5. (randomized or randomised).tw.
6. (1 or 2 or 3) and (4 or 5)
The websites of the Food and Drug Administration
(FDA) and European Medicines Evaluation Agency
(EMEA) were searched for information on efficacy and
safety. Reference lists of relevant studies and reviews
were also searched. We also searched Current Con-
trolled Trials and ClinicalTrials.gov for ongoing trials.
There were no language restrictions on the searches.
One author and one company were contacted to provide
or clarify standard deviations for two studies.
Selection
Three authors (PR, DS, PS) scanned the titles and
abstracts of every record retrieved. All potentially rele-
vant articles were read as full text. Few differences in
opinion existed, and these were resolved by a third party
(NW).
Our inclusion criteria were randomised controlled
trials that included patients with type 2 diabetes and
were: published in full, had a minimum duration of 8
weeks, and compared a GLP-1 analogue with a placebo,
insulin, an oral glucose lowering agent, or another GLP-
1 analogue, in dual or triple therapy. These inclusion
criteria were based on the comparisons which were con-
sidered to be relevant to clinical practice as suggested
by the NICE guideline [3] and by the ADA/EASD joint
statement [5].
Our exclusion criteria were trials where: GLP-1 analo-
gues were used as monotherapy, patients were naïve to
diabetes treatment, doses of GLP-1 analogues not used
in clinical practice, arms differed in glucose-lowering
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had not been first tried on metformin prior to using
GLP-1 analogues. The exception to this last criteria was
for trials done in Japan, where there is low biguanide
use and sulphonylureas are the most widely prescribed
first-line treatment for type 2 diabetes [16,17], perhaps
related to the low mean BMI (24.1 kg/m
2) seen in
Japanese people with type 2 diabetes [16]. In clinical
practice, exenatide regimen is started with 5 µg twice
daily and then increased after a month or so to 10 µg
twice daily. The dose of liraglutide is less clear, with
some trials suggesting starting with 0.6 mg, and then
increasing in stages to 1.2 mg or 1.8 mg. So trials or
arms with less than 1.2 mg daily, final dose, were
excluded except for one trial [18] where liraglutide was
used in the dose of 0.6 and 0.9 mg (standard available
dose in Japan). For newer GLP-1 agonists, we only
included dosages that were likely to be used in routine
care - i.e. those with maximal effects while minimising
adverse events.
Validity assessment
The randomised controlled trials were assessed for qual-
i t yu s i n gt h ec r i t e r i ab a s e do nt h eC o c h r a n eC o l l a b o r a -
tion’s tool for assessing risk of bias [19]. The criteria
were: method of randomisation, allocation concealment,
blinding of participants, incomplete data addressed, free
of selective reporting, groups comparable at baseline,
and sample size calculation. Description of withdrawals
or losses to follow up and reasons of withdrawals were
systematically examined. Each study was quality assessed
for the issues of incomplete outcome data or missing
data by investigating drop-outs, losses to follow-up and
withdrawals.
One of the three authors (CC, DS, PS) assessed the
quality of each trial, and the assessment was checked by
a n o t h e ra u t h o r( C C ,P R ,D S ) .A n yd i s a g r e e m e n t sw e r e
resolved by consensus between the authors.
Data abstraction
Two of the three authors (CC, DS, PS) independently
extracted data using a standard data extraction form
that was tested, piloted and modified for the current
review. Data extraction was checked by a second author
(CC, PR, DS). Relevant data on study population, inter-
vention, study design and outcomes were pulled out
from included studies. The few discrepancies found
were resolved by consensus.
Primary outcome measures were: HbA1c, weight
change and adverse effects, including hypoglycaemia.
Other outcomes included BP (blood pressure), FPG
(fasting blood glucose) and PPG (post-prandial glucose),
plasma lipids, beta cell function, and health related qual-
ity of life.
Quantitative data synthesis
Dichotomous data were expressed as the proportion of
participants achieving the target HbA1c level of ≤7, and
continuous data were expressed as weighted mean dif-
ferences with 95% CIs. Analyses were done comparing
different GLP-1 agonists against placebo or different
active comparators.
Outcomes such as HbA1c, proportion of patients with
HbAlc ≤7%, weight change and FPG were analysed using
meta-analysis because all studies reported these out-
comes using the same scale. The remaining outcomes
were described qualitatively. For dichotomous data, event
rates together with the sample size were used, whereas
changes from baseline to end and standard deviations
were computed for continuous data. Data were sum-
marised with a random effects model using Review Man-
ager 5. Heterogeneity was assessed using the I
2 test [19].
We regarded I
2 from 70% to 84% as substantial and 85%
or more as highly significant. Due to the limited number
of studies in each comparison, sensitivity analyses were
not carried out. Relevant sensitivity analyses would have
included analysis by study quality.
Results
Trial flow
One hundred and seventy full text articles were assessed
for eligibility and 142 papers were excluded. Twenty eight
randomised controlled trials fulfilled the inclusion criteria
and were included in the review (Figure 1). The main rea-
sons for exclusion were: use of GLP-1 agonists as mono-
therapy, trials were <8 weeks duration, participants were
not randomised, less than two-thirds of patients had been
first tried on metformin, and the use of doses of GLP-1
agonists not relevant to those used in practice.
Study characteristics
Of the twenty eight studies included, nineteen examined
exenatide, seven liraglutide, one albiglutide, and two tas-
poglutide (one trial examined exenatide against liraglu-
tide). The comparators included placebo, sulphonylurea,
rosiglitazone, sitagliptin, pioglitazone and various forms
of insulin. Characteristics of the included trials are
shown in Table 1. They will be referred to in this sec-
tion by the name of the first author and year of
publication.
The mean ages of the patients in the trials ranged
from 51.8 to 61.3 years, mean baseline HbA1c ranged
from 7.1% to 10.3%, and mean BMI from 25.0 to 35.0
kg/m
2. The duration of the trials ranged from 8 to 52
weeks (the majority of the trials lasted 24 weeks or
longer and two studies lasted 52 weeks). The mean
number of participants in trials was 383 (range 51 to
1091); however, eight studies had fewer than 50
participants.
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tion or sponsorship from the manufacturer of the trial
drug. Buse 2009 (the trial of liraglutide versus exenatide)
was sponsored by Novo Nordisk, the manufacturer of
liraglutide.
In some studies there were some uncertainties or
inequalities regarding previous or concomitant anti-dia-
betic treatment. Patients in Marre 2009 (LEAD-1) were
assumed to have been on previous metformin therapy, but
this was not reported in the study. In Davis 2007, there
687 of records identified through 
database searching
363 records after duplicates 
removed
265 records retained
98 records excluded due to 
meeting exclusion criteria 
on basis of title 
170 full-text articles assessed 
for eligibility
51 RCTs retained for 
further detailed analysis
95 articles excluded due 
to meeting exclusion 
criteria on basis of 
abstract 
119 additional articles 
excluded due to meeting 
at least one exclusion 
criteria of this review
28 studies included in 
systematic review 
RCTs excluded;
GLP-1 agonists used as 
monotherapy (7)
<8 weeks duration (5)
doses used not clinically 
relevant (4)
patients naïve to 
treatment (3)
less than two thirds of 
patients first failed on 
metformin (2)
patients not randomised 
(2)
Figure 1 Flow chart of search results.
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Study and Country Interventions Characteristics of participants Study
duration
Outcomes measured
ALBIGLUTIDE
Rosenstock 2009 [23];
USA, Mexico, Chile,
Dominican Republic
1) Albiglutide 30 mg weekly
2) Albiglutide 30 mg every
two weeks
3) Placebo
All groups also received Met
(The arms with other doses of
albiglutide and exenatide excluded
from this review)
number: 361 (31/32/51)
mean age: 54.0 to 55.5 years
gender: 45.1 to 74.2% female
HbA1c (%): Albi Weekly 30 mg: 8.0,
Placebo: 7.9, Albi every 2 weeks 30
mg: 8.0
BMI (kg/m
2): Albi weekly 30 mg:
33.0, Albi every 2 weeks 30 mg: 31.2,
Placebo: 31.8
ethnicity: Caucasian (43.8 to 71%)
diabetes duration: 4.9 years (3.9 to
5.2 years)
previous medication: diet and
exercise only: 29.0 to 34.4%, Met: 65.6
to 71.0%
16
weeks
primary: HbA1c
other: FPG, fasting fructosamine, C-
peptide, glucagon, insulin, lipid
profiles, beta-cell function
(homeostasis model), adverse events
and safety analyses
EXENATIDE
Apovian 2010 [43]; US;
11 sites
1) Exenatide 10 μg twice daily
2) Placebo
All groups also received
intensive life style
modifications and Met/Met +
Su/Su
number: 196 (97/99)
mean age: 54.5 to 55.1
gender: 62 to 63% female
HbA1c (%): Exe 10 μg BID: 7.7;
Placebo: 7.5
BMI (kg/m
2): Exe 10 μg BID: 33.6;
Placebo: 33.9
ethnicity: NR
diabetes duration: 5.3 to 5.7 years
previous medication: Met; Met + Su;
Su
24
weeks
primary: body weight
other: HbA1c, 6-point SMBG profiles,
waist circumference, HOMA-B, HOMA-
S, fasting lipids, proportion of
participants with weight loss >5% and
10%, SBP and DBP and subgroup
analysis by oral agents
Bergenstal 2009 [28];
USA
1) Exenatide 10 μg twice daily
2) BIAsp 30 twice daily
3) BIAsp 30 once daily
All groups also received Met +
Su (glim)
number: 372 (124 in each
comparison group)
mean age: 51.8 to 53.4 years
gender: 51.6 to 52.4% female
HbA1c (%): Exe 10 μg BID: 10.2;
BIAsp 30 OD: 10.1; BIAsp 30 BID: 10.3
BMI (kg/m
2): Exe 10 μg BID: 34.2;
BIAsp 30 OD: 33.7; BIAsp 30 BID: 33.5
ethnicity: 59.7 to 67.7% White; 18.5%
to 26.6% Black; 1.6 to 2.4% Asian
diabetes duration: 8.4 to 9.9 years
previous medication: Met + Su
24
weeks
primary: HbA1c
other: FPG; 8 point plasma glucose
profiles changes in body weight;
superiority and inferiority tested,
adverse events
Bergenstal 2010 [37];
USA, India, Mexico; 72
sites
1) Exenatide 2 mg once
weekly
2) Sitagliptin 100 mg once
daily
3) Pioglitazone 45 mg once
daily
All groups also received Met +
placebo
number: 491 (160/166/165)
mean age: 52 to 53 years
gender: 44 to 52% female
HbA1c (%): Exe 2 mg QW: 8.6; Sita
100 mg OD: 8.5; Pio 45 mg OD: 8.5
BMI (kg/m
2): Exe 2 mg QW: 32; Sita
100 mg OD: 32; Pio 45 mg OD: 32
ethnicity: 30 to 39% White; 8 to 12%
Black; 27 to 31% Hispanic; 23 to 25%
Asian; 0 to 2% Native American; 1 to
2% other
diabetes duration: 5 to 6 years
previous medication: Met
26
weeks
primary: HbA1c
other: proportion of participants
achieving HbA1c level ≤7% or ≤6.5%;
FPG ≤7 mmol/l; 6-point SMBG;
bodyweight; lipid profile; BP;
cardiovascular risk markers; health-
related outcomes; adverse events;
hypoglycaemia; exenatide antibodies
Bunck 2009 [29]; 1) Exenatide 10 μg twice daily
2) Glargine 10 IU day, titrated
accordingly
number: 69 (36/33)
mean age: 58.3 to 58.4 years
52
weeks
primary: Beta-cell function
other: HbA1c; FPG; body weight;
insulin sensitivity;
Netherlands, Finland,
Sweden, USA
Both groups also received Met gender: 33.3 to 36.1% female
HbA1c (%): Exe 10 μg BID: 7.6; Glar:
7.4
BMI(kg/m
2): Exe 10 μg BID: 30.9; Glar:
30.1
ethnicity: NR
diabetes duration: 4.0 to 5.7 years
previous medication: Met
safety; hypoglycaemia (BG <3.3 mmol/
L)
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Davies 2009 (HEELA)
[30]; UK
1) Exenatide 10 μg twice daily
2) Glargine 10 IU/day, titrated
accordingly
Both groups also remained on
previous therapy: Met +/- Su
+/- Tzd
number: 235 (118/117)
mean age: 56.2 to 56.8 years
gender: 29.7 to 33.6% female
HbA1c (%): Exe 10 μg BID: 8.65; Glar:
8.48
BMI (kg/m
2): Exe 10 μg BID: 34.6;
Glar: 33.7
ethnicity: NR
diabetes duration: 8.4 to 9.0 years
previous medication: Met + Su:
42.3%; Met + Tzd: 13.7%; Su + Tzd:
2.6%; Met + Su + Tzd: 40.6%
26
weeks
primary: proportion of patients with
an HbA1c level ≤7.4% and weight
gain ≤1 kg i.e. composite outcome.
other: body weight, waist
circumference, FPG, serum lipids, BP,
adverse events, hypoglycaemia
Davis 2007 [31]; USA 1) Exenatide 10 μg twice daily
2) Insulin (remained on pre-
study insulin regimen)
Both groups also received Met
+S u
number: 51 (35/16)
mean age: 52 to 54 years
gender: 50 to 54% female
HbA1c (%): Exe 10 μg BID: 8.0; Ins:
8.3
BMI (kg/m
2): Exe 10 μg BID: 33; Ins:
35
ethnicity: NR
diabetes duration: 10.4 to 11.9 years
previous medication: Met only: 43%;
Su only: 8%; Met + Su: 49%; GLAR:
20%; NPH insulin: 2%; Ultralente: 2%;
mixtures: 20%; multiple insulin
therapies: 14%
16
weeks
primary: maintenance of glycaemic
control, predefined as an HbA1c
increase of <0.5%
other: body weight; SMBG profiles;
adverse events; hypoglycaemic events
DeFronzo 2005 [42];
USA
1) Exenatide 10 μg twice daily
2) Placebo
All groups also received Met
(other dose of exenatide, 5 μg BID,
excluded from this review)
number: 336 (113/113)
mean age: 52 to 54 years
gender: 39.8 to 40.7% female
HbA1c (%): Exe 10 μg BID: 8.18;
Placebo: 8.2
BMI(kg/m
2): 34
ethnicity: 72.6 to 79.6% Caucasians;
8.8 to 13.3% Black; 8 to 10.6%
Hispanic; 3.5% other
diabetes duration: 4.9 to 6.6 years
previous medication: Met
30
weeks
primary: HbA1c
other: safety, hypoglycaemia; anti-
exenatide antibodies); FPG and PPG
fasting proinsulin; lipids
DeFronzo 2010 [22];
USA
1) Exenatide 10 μg twice daily
2) Rosiglitazone 4 mg twice
daily
(one arm receiving both exenatide
and rosiglitazone was excluded
from the review)
All groups also received Met
number: 137 (45/45)
mean age: 56 years
gender: 49% female
HbA1c (%): 7.8
BMI: 32.5
diabetes duration: 3.7 to 4.7 years
ethnicity: Caucasian, 61%, Hispanic
23%; African American 12%; Others
4%
previous medication: Met ≥ 1500
mg/day
20
weeks
primary: measurement of glucose
potentiated arginine stimulated
incremental area under the curve
during hyperglycaemic clamp test
other: glucose AUC, HbA1c, glucose,
insulin, C-peptide, lipids and body
weight, adverse events, vital signs,
haematology and chemistries.
Derosa 2010 [27]; Italy 1) Exenatide 10 μg twice daily
2) Glibenclamide 5 mg, 3
times daily
Both groups also received Met
number: 128 (63/65)
mean age: 57 to 56 years
gender: 52 to 49% female
HbA1c (%):Exe 10 μg BID: 8.8; Glib:
8.9
BMI (kg/m
2): Exe 10 μg BID: 28.7;
Glib: 28.5
ethnicity: all white
diabetes duration: NR
previous medication: Met at mean
dose of 1,500 ± 500 mg/day
12
months
primary: body weight, glycaemic
control, b-cell function
other: insulin resistance and
inflammatory state parameters
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Diamant 2010 [34];
USA
1) Exenatide 2 mg once a
week
2) Insulin glargine once daily
number: 456 (233/223)
mean age: 58 years
gender: 45 to 48% female
HbA1c (%): Exe 2 mg QW: 8.3; Glar:
8.3
BMI (kg/m
2): Exe 2 mg QW: 32; Glar:
32
Ethnicity: African American up to 1%,
White 82 to 85%, Asian 6%, Hispanic
9 to 12%
diabetes duration: 7.8 to 8.0 years
previous medication: Met: 70%; Met
plus Su: 30%
26
weeks
primary: HbA1c
other: proportion of participants
reaching HbA1c <7.0% and 6.5%, FPG,
self-monitored blood glucose, body
weight, lipids, HOMA levels, health
outcomes, adverse events,
hypoglycaemia
Drucker 2008 [41];
Canada/USA
1) Exenatide 10 μg twice daily
2) Exenatide 2 mg once
weekly
Both groups also remained on
previous therapy: diet/exercise
or Met, Su, or Tzd as
monotherapy or combination of
any two.
number: 303 (147/148)
mean age: 55 years
gender: 45 to 49% female
HbA1c (%): Exe 2 mg QW: 8.3; Exe
10 μg BID: 8.3
BMI (kg/m
2): Exe 2 mg QW: 35; Exe
10 μg BID: 35
ethnicity: 73 to 83% White, 6 to 13%
Black, 11 to 14% Hispanic, 0 to 1%
Asian
diabetes duration: 6 to 7 years
previous medication: Monotherapy:
43% to 46%, combination therapy: 36
to 39%; all Met: 69 to 77%, all Su:
37%, all Tzd: 15 to 17%; diet/exercise
only: 14 to 16%
30
weeks
primary: HbA1c
other: safety and tolerability, body
weight, FPG, PPG, fasting lipids,
fasting glucagon, BP, adverse events,
patients who lost glucose control,
hypoglycaemic episodes (symptoms
and PG <3 mmol/l)
Gao 2009 [45]; China,
India, Korea, Taiwan
1) Exenatide 10 μg twice daily
2) Placebo
Both groups also remained on
previous therapy: Met and/or
Su
number: 472 (238/234)
mean age: 54 to 55 years
gender: 52 to 59% female
HbA1c (%): 8.3 (in both groups)
BMI (kg/m
2): 26.1 to 26.4
ethnicity: all Asian (Chinese 49.6 to
53%; Indian 20.3 to 21.4%; Korean
16.4 to 17.9%; Taiwanese 10.3 to
11.1%)
diabetes duration: 8 years
previous medication: Met alone:
19.2 to 19.8%; Met and Su: 80.2 to
80.8%
16
weeks
primary: HbA1c
other: body weight; hypoglycaemic
events (symptoms and BG <3.3
mmol/l); FPG; PPG, adverse events,
exenatide antibody levels
Gill 2010 [26];
Canada and
Netherland
1) Exenatide 10 μg twice daily
2) Placebo
Both groups also remained on
previous therapy: Met and/or
Tzd antihypertensives remained
constant
number: 54 (28/26)
mean age: 54 to 57 years
gender: 32 to 58% female
HbA1c (%): 7.1 to 7.5
BMI (kg/m
2): 29.5 to 30.1
ethnicity: Caucasian 86 to 96%;
African 0 to 7%; East Asian 1%;
Hispanic 0 to 1%
diabetes duration: 6 to 7 years
previous medications: Met±Tzd;
antihypertensives
12
weeks
primary: 24 hour heart rate (HR)
other: HbA1c; body weight hourly;
SBP; DBP; rate pressure product;
hourly HR; daytime/night time HR;
mean arterial pressure
Heine 2005 [32]; 13
countries (Australia, 9
European countries,
Brazil, Puerto Rico,
USA)
1) Exenatide 10 μg twice daily
2) Glargine 10 IU/day, titrated
accordingly
Both groups also received Met
and Su
number: 551 (282/267)
mean age: 58 to 59.8 years
gender: 43.4 to 45.0% female
HbA1c (%): Exe 10 μg BID: 8.2; Glar:
8.3
BMI: Exe 10 μg BID: 31.4; Glar: 31.3
ethnicity: 79.8 to 80.5% White; 0.7 to
1.1% Black; 0.7 to 1.8% Asian; 15 to
15.6% Hispanic; 2.1 to 2.6% other
diabetes duration: 9.2 to 9.9 years
previous medication: Met+ Su
26
weeks
primary: HbA1c
other: body weight, FPG, blood
glucose, patient reported health
outcome measures, adverse events,
hypoglycaemia
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Kadowaki 2009 [20];
Japan
1) Exenatide 10 μg twice daily
2) Placebo
Both groups also remained on
previous medication: Su or Su
+Met or Su +Tzd
(Two other doses of exenatide, 2.5
μg BID and 5 μg BID were
excluded from this review)
number: 153 (37/40)
mean age: 57.8 to 60.5 years
gender: 25 to 38% female
HbA1c (%): Exe 10 μg BID: 7.9;
Placebo: 8.1
BMI(kg/m
2): Exe 10 μg BID: 26.1;
Placebo: 25.8
ethnicity: presumably all Japanese
diabetes duration: 9.6 to 11.9 years
previous medication: Su alone: 8.1
to 10%; Su + alpha-GI: 0 to 2.7%; Su
+ Met: 45 to 48.6%; Su + Met +
alpha-GI: 18.9 to 22.5%; Su + Met +
meglitinide derivative: 0 to 2.7%; Su +
Tzd: 5.4 to 10%; Su + Tzd + alpha-GI:
12.5 to 13.5%
12
weeks
primary: HbA1c
other: FPG; body weight; serum
lipids, adverse events, hypoglycaemia
(SMBG <3.9 mmol/l), amylase,
antibodies to exenatide
Kendall 2005 [21];
USA
1) Exenatide 10 μg twice daily
2) Placebo (2 placebo arms
combined)
Both groups also remained on
Met + Su
(other dose of exenatide, 5 μg BID,
excluded from this review)
number: 733 (241/247)
mean age: 55 to 56 years
gender: 40.7 to 44.1% female
HbA1c (%): Exe 10 μg BID: 8.5;
Placebo: 8.5
BMI: Exe 10 μg BID: 34; Placebo: 34
ethnicity: 66.4 to 69% White; 11.6 to
12.1% Black; 15.8 to 16.6% Hispanic;
1.6 to 2.9% Asian; 0.4 to 0.8% Native
American; 1.6 to 2% other
diabetes duration: 8.7 to 9.4 years
previous medication: Met and Su
30
weeks
primary: HbA1c
other: FPG, PPG, body weight, lipids,
adverse events, clinical laboratory
tests, hypoglycaemia (BG <3.3 mmol/l)
Nauck 2007 [33]; 13
countries
1) Exenatide 10 μg twice daily
2)BIAsp 30 twice daily
Both groups also remained on
Met + Su
number: 501 (253/248)
mean age: 58 to 59 years
gender: 47 to 51% female
HbA1c (%): Exe 10 μg BID: 8.6; BIAsp
30: 8.6
BMI (kg/m
2): Exe 10 μg BID: 30.6;
BIAsp 30: 30.2
ethnicity: NR
diabetes duration: 9.8 to 10.0 years
previous medication: Met and Su
52
weeks
primary: HbA1c
other: FPG, PPG, SMBG profiles, beta-
cell function, body weight, adverse
events, anti-exenatide antibodies,
hypoglycaemia (symptoms or BG <3.4
mmol/L)
Zinman 2007 [67];
Canada, Spain, USA
1) Exenatide 10 μg twice daily
2) Placebo
Both groups also remained on
previous
medication: Tzd +/- Met
number: 233 (121/112)
mean age: 55.6 to 56.6 years
gender: 42.9 to 46.3% female
HbA1c (%): Exe: 7.9; Placebo: 7.9
BMI (kg/m
2): Exe: 34; Placebo: 34
ethnicity: 82.1 to 85.1% White; 14.9
to 17.9% other
diabetes duration: 7.3 to 8.2 years
previous medication: Tzd alone: 19.6
to 23%; Tzd + Met: 76.9 to 80.4%
16
weeks
primary: HbA1c
other: FPG, body weight, SMBG levels,
HOMA levels, blood chemistry for
safety monitoring; hypoglycaemia
LIRAGLUTIDE
Kaku 2010 [18];
Japan; 49 centres
1) Liraglutide 0.6 mg once
daily
2) Liraglutide 0.9 mg once
daily
3) Placebo
All groups also received Su
number: 264 (88/88/88)
mean age: 58.6 to 61.3
gender: 33 to 40% female
HbA1c (%): Lir 0.6 mg: 8.6; Lir 0.9
mg: 8.21; Placebo: 8.45
BMI (kg/m
2): Lir 0.6 mg: 25.3; Lir 0.9
mg: 24.4; Placebo: 24.9
ethnicity: All Japanese
diabetes duration: 9.3 to 11.6 years
previous medication: Su
24
weeks
primary: HbA1c
other: 7-point SMBG profiles, body
weight, FPG, PPG, lipid profile and
biomarkers for cardiovascular effects,
proportions of subjects reaching
HbA1c <7% or <6.5%
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Marre 2009 (LEAD 1)
[39]; 21 countries
(mainly in Europe and
Asia)
1) Liraglutide 1.2 mg once
daily
2) Liraglutide 1.8 mg once
daily
3) Placebo
4) Rosiglitazone 4 mg once
daily
All groups also received Su
(Glim)
(Lir 0.6 was excluded in this
review)
number: 1041 (228/234/114/232)
mean age: 54.7 to 57.7 years
gender: 47 to 55% female
HbA1c (%): Lir 1.2 mg: 8.5; Lir 1.8
mg: 8.5; Placebo: 8.4; Rosi: 8.4
BMI (kg/m
2): Lir 1.2 mg: 29.8; Lir 1.8
mg: 30; Placebo: 30.3; Rosi: 29.4
ethnicity: NR
diabetes duration: (median, 25
th and
75
th percentile) 6.5 to 6.7 years
previous medication: monotherapy:
27/32%, combination: 68/73%
26
weeks
primary: HbA1c
other: body weight, FPG, PPG, beta-
cell function, BP; superiority of
liraglutide to placebo and non-
inferiority to rosiglitazone,
hypoglycaemic episodes(PG <3.1
mmol/L), liraglutide antibodies,
tolerability (gastrointestinal
complaints), adverse events,
biochemical and haematological
parameters, calcitonin, vital signs, ECG
Nauck 2009 (LEAD 2)
[36]; Multinational (21
countries)
1) Liraglutide 1.2 mg once
daily
2) Liraglutide 1.8 mg once
daily
3) Glimepiride 4 mg once daily
4) Placebo
All groups also received Met
(Lir 0.6 was excluded in this
review)
number: 1091(240/242/242/121)
mean age: 56 to 57 years
gender: 40 to 46% female
HbA1c (%): Lir 1.2 mg: 8.3, Lir 1.8
mg: 8.4, Su: 8.4, Placebo: 8.4
BMI (kg/m
2): Lir 1.2 mg: 31.1, Lir 1.8
mg: 30.9, Su: 31.2, Placebo: 31.6
ethnicity: 88 to 89% White, 2 to 4%
Black, 7 to 9% Asian, 1 to 3% other
diabetes duration: 7 to 8 years
previous medication: 62 to 66%
combination, 34 to 38% monotherapy
(86 to 93% Met)
26
weeks
primary: HbA1c
other: body weight, FPG, PPG, beta
cell function, adverse events,
biochemical and haematology
measures, hypoglycaemic episodes
(symptoms and PG <3.1 mmol/L), vital
signs, ECG
Pratley 2010 [38]; 11
European countries;
USA and Canada; 158
office-based sites
1) Liraglutide 1.2 mg once
daily
2) Liraglutide 1.8 mg once
daily
3) Sitagliptin 100 mg once
daily
All groups also received Met
number: 665 (225/221/219)
mean age: 55 to 55.9
gender: 45 to 48% female
HbA1c (%): Lir 1.2 mg: 8.4, Lir 1.8
mg: 8.4, Sita 100 mg: 8.5
BMI (kg/m
2): Lir 1.2 mg: 32.6, Lir 1.8
mg: 33.1, Sita 100 mg: 32.6
ethnicity: 82 to 91% White (15 to
17% Hispanic or latino), 5 to 10%
Black, 1 to 3% Asian or Pacific
Islander, 4 to 5% Other
diabetes duration: 6.0 to 6.4 years
previous medications: Met
26
weeks
primary: HbA1c
other: superiority and non-inferiority
comparisons, proportion of
participants reaching HbA1c targets of
<7 %o r≤6.5%, FPG, PPG, body
weight, b-cell function, fasting lipid
profiles, cardiovascular markers, BP,
HR, physical measures, treatment
satisfaction, hypoglycaemia
Zinman 2009 (LEAD 4)
[44]; USA and Canada
1) Liraglutide 1.2 mg once
daily
2) Liraglutide 1.8 mg once
daily
3) Placebo
All groups also received Met
and Tzd (Rosi)
number: 533(178/178/177)
mean age: 55 years
gender: 38 to 49% female
HbA1c (%): Lir 1.2 mg: 8.5, Lir 1.8
mg: 8.6, Placebo: 8.4
BMI (kg/m
2): Lir 1.2 mg: 33.2, Lir 1.8
mg: 33.5, Placebo: 33.9
ethnicity: 81 to 84% White, 10 to
15% Black, 13 to 16% Hispanic, 1 to
3% Asian, 3 to 4% Others
diabetes duration: mean 9 years
previous medication: 16 to 18%
monotherapy, 82 to 84% combination
therapy
26
weeks
primary: HbA1c
other: body weight, FPG, PPG, beta-
cell function, BP, lipids, adverse
events, biochemical and haematology
measures, and hypoglycaemic
episodes (PG <3.1 mmol/L),
superiority of liraglutide tested,
vital signs, ECG
Russell Jones 2005
(LEAD 5) [35];
Multinational (17
countries)
1) Liraglutide 1.8 mg once
daily
2) Placebo
3) Glargine (avg. dose 24IU/day)
All groups also received Met
and Su
number: 581(230/114/232)
mean age: 57.5 to 57.6 years
gender: 40 to 51% female
HbA1c (%): Lir: 8.3, Placebo: 8.3, Glar:
8.2
BMI (kg/m
2): Lir: 30.4, Placebo: 31.3,
Glar: 30.3
ethnicity: NR
diabetes duration: mean 9.2 to 9.7
years
previous medication: 5t o6 %
monotherapy, 94 to 95% combination
treatment)
26
weeks
primary: HbA1c
other: weight, FPG, eight point
plasma glucose profiles, beta-cell
function, BP, adverse events,
hypoglycaemic episodes
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Page 9 of 26were substantial imbalances in concomitant treatment i.e.
12% of patients in the exenatide group being on previous
sulphonylurea only, and none in the insulin group; also,
insulin therapy in the comparison group was not opti-
mised. In Bergenstal 2009, sulphonylurea was discontinued
in the BIAsp 30 twice daily group to reduce the risk of
hypoglycaemia, but not in the other groups where patients
received both a sulphonylurea and metformin.
The primary outcome measure in most trials was
change in HbA1c value from baseline to the end of the
study. In all trials except one, more than 70% of the
patients were on metformin. In Kaku 2010 all the parti-
cipants were primarily on sulphonylureas (the standard
first line oral antidiabetic drug in Japan) [16].
Groups excluded from this review
We excluded some arms of the included trials. In two
trials [20,21] the group of patients taking non clinically
relevant dose of exenatide were excluded. In DeFronzo
2010 [22] the participants taking both exenatide and
rosiglitazone were excluded. Some doses of albiglutide
[23] and taspoglutide [24] used in dose ranging trials
were excluded, as, based on the results or the author’s
conclusions, they seemed unlikely to be used in clinical
practice. In Rosenstock 2009 [23], a group receiving exe-
natide was excluded, as all participants in this group
also received metformin, whereas only a proportion of
the patients in the other groups did. Ratner 2010 [25]
compared three doses of taspoglutide (20 mg once
weekly escalated to 20 mg, 30 mg and 40 mg once
weekly). In this review, we only considered 20 mg once
weekly escalated to 20 mg once weekly.
Study quality
Studies were mainly of moderate to high quality, with
most studies fulfilling five to seven of the seven quality
criteria. Note that blinding was not practical in some
Table 1 Characteristics of the included studies (Continued)
Buse 2009 (LEAD 6)
[40]; 15 countries
1) Liraglutide 1.8 mg once
daily
2) Exenatide 10 μg twice daily
Both groups also remained on
previous medications: Met +/-
Su
number: 464(233/231)
mean age: 56 to 57 years
gender: 45 to 51% female
HbA1c: Lir: 8.2, Exe: 8.1
BMI: Lir: 32.9, Exe: 32.9
ethnicity: 91 to 93% White, <1 to 2%
Asian, 5 to 6% Black, 1 to 2% other
diabetes duration: mean 7.9 to 8.5
years
previous medication: 62 to 64% Met
plus Su, 27% Met monotherapy, 9 to
10% Su monotherapy
26
weeks
primary: HbA1c
other: FPG, body weight, SMBG
profile, beta cell function, BP, lipid
profiles, overall treatment satisfaction,
adverse events, biochemical and
haematological measures,
hypoglycaemic episodes, vital signs,
ECG
TASPOGLUTIDE
Nauck 2009 [24];
Germany and
Switzerland
1) Taspoglutide 10 mg once
weekly
2) Taspoglutide 20 mg once
weekly
3) Taspoglutide 20 mg once
every two weeks
4) Placebo
All groups also received Met
(For this review, the following
groups were excluded: 5 mg
weekly and 10 mg every 2 weeks)
number: 306 (49/50/49/49)
mean age: 56 years
gender: 39 to 64% female
HbA1c (%): Placebo: 8.0, Tas 10 mg
QW: 7.9, Tas 20 mg QW: 7.8, Tas 20
mg Q2W: 7.9
BMI (kg/m
2): Placebo: 31.8, Tas 10
mg QW: 32.6, Tas 20 mg QW: 32.4,
Tas 20 mg Q2W: 33.2
ethnicity: NR
diabetes duration: mean 5 to 6
years
previous medication: Met
monotherapy (mean 1888 mg to
2019 mg)
8 weeks primary: HbA1c
other: FPG, body weight,
fructosamine, C-peptide, fasting
insulin, pro-insulin-to-insulin ratio,
fasting glucagon, lipids, adverse
events, clinical laboratory tests, local
tolerance at the injection site, anti-
taspoglutide antibodies, vital signs,
ECG
Ratner 2010 [25];
Australia, France,
Germany, Mexico,
Peru and USA; 27
sites
1) Taspoglutide 20 mg once
weekly
2) Placebo
All groups also received Met
(For this review, the following
groups were excluded: 20 mg once
weekly titrated to 30 mg and 40
mg once weekly)
number: 133 (32/32)
mean age: 56 to 57 years
gender: 53 to 59% of female
HbA1c (%): Tas 20 mg QW: 8.0,
Placebo: 7.8
BMI (kg/m
2): Tas 20 mg QW: 33.3,
Placebo: 33.2
ethnicity: NR
diabetes duration: 6 to 7 years
previous medications: Met
8 weeks
+4
weeks
follow
up
primary: GI tolerability
other: HbA1c, FPG, body weight and
pharmacokinetics parameters
Albi: Albiglutide; Exe: Exenatide; Lir: Liraglutide; Tas: Taspoglutide; Ins: Insulin; Glar: Insulin glargine; Tzd: Thiazolidinedione; Rosi: Rosiglitazone; Sita: Sitagliptin; Su:
Sulphonylureas; Glim: Glimepiride; Met: Metformin; OD/QD: Once daily; BID: Twice daily; TID: Thrice daily; QW: Once weekly; HbA1c: Glycated haemoglobin; BMI:
Body mass index; FPG: Fasting plasma glucose; PPG: Postprandial glucose; BG; Blood glucose; PG: Plasma glucose; BP: Blood pressure; SMBG: Self monitoring of
blood glucose; HOMA: Homeostasis model assessment; ECG: Electrocardiogram; NR: Not reported; HEELA: Helping Evaluate Exenatide in patients with diabetes
compared with Long-Acting insulin; LEAD: Liraglutide Effect and Action in Diabetes
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Four studies only fulfilled four of the criteria, while ten
fulfilled five criteria, seven fulfilled six criteria, and
seven fulfilled seven criteria. As shown in Table 2 many
studies had one or more arms with losses to follow-up
of 20% or more.
Results
HbA1c
Figure 2 shows the meta-analysis of the percentage
change in HbA1c for the GLP-1 agonist trials in com-
parison with placebo. It can be seen that all GLP-1 ago-
nists significantly reduced HbA1c, with reductions
ranging from 0.62% to 1.16%. Two studies [24,26] could
not be included in the meta-analysis due to insufficient
details reported. Gill 2010 [26] compared exenatide 10
µg twice daily versus placebo. The mean difference
between groups was not significant (0.3% SD 1.06).
However, this trial was a small, short term trial powered
to detect differences in mean 24-hr heart rate (not
HbA1c). Nauck 2009 [24] compared taspoglutide at
d o s e so f5m g ,1 0m ga n d2 0m go n c ew e e k l y ,a n d1 0
mg and 20 mg once every two weeks, and found all
doses changed significantly compared to placebo. This
s t u d yc o u l dn o tb ei n c l u d e di nt h em e t a - a n a l y s i s
because of lack of data on standard deviations (SDs) or
standard errors (SEs).
The results of forest plots of GLP-1 agonists against
active comparators are shown in Figure 3. Derosa 2010
[27] could not be included due to insufficient details
(SDs) reported.
GLP-1 agonists versus insulin
Six RCTs [28-33] compared exenatide (10µg twice daily)
with insulin (BIAsp, glargine or mixed insulin regimens),
one [34] compared long acting exenatide (2 mg once
weekly) with glargine and one [35] compared liraglutide
with glargine. Two studies [28,33] compared BIAsp 30
twice daily with exenatide twice daily. Nauck 2007 [33]
found a non significant difference in favour of exenatide,
but Bergenstal 2009 [28] reported a significantly greater
reduction in HbA1c with BIAsp 30 twice daily (1.0%, p
< 0.00001) and once daily (0.59%, p = 0.003). Bergenstal
2009 was sponsored by Novo Nordisk, the manufacturer
of BIAsp30, and the study by Nauck 2007 was spon-
sored by Lilly, the manufacturer of exenatide. The expla-
nation for the highly significant heterogeneity of I
2 =
96% between Bergenstal 2009 and Nauck 2007 may
reflect differences in baseline HbA1c (10.2% vs. 8.6%)
and BMI (33.8 vs. 30.4) respectively.
None of the three studies comparing exenatide with
insulin glargine (Bunck 2009, Davies 2009 and Heine
2005) [29,30,32] found a significant difference, and nor
did Davis 2007 [31], which compared patients remaining
on their existing insulin regimen with patients switching
to exenatide. Diamant 2010 [34] found a slightly greater
reduction in HbA1c with exenatide 2 mg once weekly
than with insulin glargine (-1.5 vs. -1.3%; p = 0.03). Lira-
glutide 1.8 mg daily caused a slightly greater reduction
in HbA1c than did insulin glargine (-1.3 vs. -1.0%; p =
0.0003) in the Russell-Jones 2009 [35] (LEAD-5) trial,
but the dose of glargine used may have been sub-
optimal.
GLP-1 agonists versus sulphonylureas
Derosa 2010 [27] found similar reductions in HbA1c
level for exenatide compared with glibenclamide 2.5 mg
three times daily (-1.50 vs. -1.80%) and Nauck 2009 [36]
(LEAD-2) found no significant difference between either
liraglutide 1.2 or 1.8 mg daily and glimepiride 4 mg
daily; HbA1c was reduced by 1% in all treatment groups.
GLP-1 agonists versus pioglitazone
Bergenstal 2010 [37] found a slightly greater reduction in
HbA1c level with exenatide 2 mg once weekly than with
pioglitazone 45 mg once daily (-1.5 vs. -1.2%; p = 0.02).
GLP-1 agonists versus sitagliptin
Bergenstal 2010 [37] found a significantly greater reduc-
tion in HbA1c with exenatid e2m go n c ew e e k l yt h a n
sitagliptin 100 mg once daily (-1.5 vs. -0.9%; p <
0.00001). Pratley 2010 [38] found that liraglutide 1.2 mg
daily led to significantly greater reduction in HbA1c
level than with sitagliptin 100 mg once daily (-1.24 vs.
-0.9%; p < 0.00001).
GLP-1 agonists versus rosiglitazone
DeFronzo 2010 [22] found similar reductions in HbA1c
level for exenatide compared with rosiglitazone 4 mg
twice daily (-0.9 vs. -1.0%). By contrast, the Marre 2009
[39] (LEAD-1) trial found that the reduction in HbA1c
level was significantly greater with liraglutide 1.2 mg
and 1.8 mg daily compared with rosiglitazone 4 mg
daily (-1.08 and -1.13 vs. - 0.44%; p < 0.0001).
GLP-1 agonists versus GLP-1 agonists
In the Buse 2009 [40] (LEAD-6) trial, liraglutide 1.8 mg
daily led to significantly greater reduction in HbA1c
than exenatide 10 μg twice daily (-1.12% vs. - 0.79%; p =
0.004). Drucker 2008 [41] found that long acting exena-
tide (2 mg once weekly) was found to cause a greater
reduction in HbA1c than exenatide 10 μgt w i c ed a i l y
(-1.9% vs. -1.5%, mean difference 0.40 (95% CI: 0.12,
0.68), p = 0.005).
The meta-analysis of the trials involving arms with
both 1.2 mg and 1.8 mg daily doses of liraglutide
showed a non-significant difference of -0.10% (95% CI
-0.03 to 0.23) in favour of the 1.8 mg dose.
Percentage of patients achieving HbAlc ≤7%
As expected, the proportion of participants achieving an
HbA1c level of 7% or less was significantly greater with
all GLP-1 agonists compared to placebo (shown in Fig-
ure 4). As with the overall HbA1c reduction, there are
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Study Adequate
sequence
generation
Allocation
concealment
Blinding Incomplete
outcome data
addressed
Percentage who completed
the trial
Free of
selective
reporting
Groups
comparable
at baseline
Sample
size
calculation
Rosenstock
2009 [23]
Unclear Unclear Yes,
Double
blind
Yes Albi 30 mg QW/Albi 30 mg
every two weeks/P: 71.0/75.0/
78.4
Yes Yes Yes
Apovian
2010 [43]
Yes Yes Yes,
Double
blind
Yes Exe/P: 72.2/72.7 Yes Yes Yes
Bergenstal
2009 [28]
Yes Yes No,
Open
label
Yes Exe/BIAsp QD/BIAsp BID: 70.2/
83.9/80.6
Yes Yes Yes
Bergenstal
2010 [37]
Yes Yes Yes,
Double
blind
Yes Exe/Sita/Pio: 79.4/86.7/79.4 Yes Yes Yes
Bunck 2009
[29]
Yes Unclear Unclear Yes Exe/Glar: 83.3/90.9 Yes Yes Yes
Davies 2009
(HEELA) [30]
Yes Unclear No,
Open
label
Yes Exe/Glar: 83.9/88.9 Yes Yes Yes
Davis 2007
[31]
Unclear Unclear No,
Open
label
Yes Exe/Ins: 57.6/93.8 Yes Yes Yes
DeFronzo
2005 [42]
Unclear Unclear Yes,
Triple
blind
Yes Exe/P: 82.3/78.8 Yes Yes Yes
DeFronzo
2010 [22]
Yes Unclear No,
Open
label
Yes Exe/Rosi: 73.3/75.6 Yes Yes No
Derosa 2010
[27]
Yes Yes No,
Single
blind
Yes Exe/Glib: 93.7/87.7 Yes Yes No
Diamant
2010 [34]
Yes Yes No,
Open
label
Yes Exe/Glar: 89.7/93.7 Yes Yes Yes
Drucker
2008 [41]
Unclear Unclear No,
Open
label
Yes Exe/Exe lar: 88.4/86.5 Yes Yes Yes
Gao 2009
[45]
Yes Yes Yes,
Double
blind
Yes Exe/P: 81.1/88.9 Yes Yes Yes
Gill 2010
[26]
Unclear Unclear Yes,
Double
blind
Yes Exe/P: 78.6/88.5 Yes Yes Yes
Heine 2005
[32]
Yes Yes No,
Open
label
Yes Exe/Glar: 80.9/90.6 Yes Yes Yes
Kadowaki
2009 [20]
Unclear Unclear Yes,
Double
blind
Yes Exe/P: 83.8/97.5 Yes Yes Yes
Kendall 2005
[21]
Unclear Unclear Yes,
Double
blind
Yes Exe/P: 82.6/76.1 Yes Yes Yes
Nauck 2007
[33]
Yes Yes Unclear Yes Exe/BIAsp 30 BID: 78.7/89.9 Yes Yes Yes
Zinman
2007 [67]
Yes Yes Yes,
Double
blind
Yes Exe/P: 71.1/85.7 Yes Yes Yes
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nists. Figure 5 shows the risk ratios of the proportion of
participants achieving a target HbAlc level of ≤7% with
GLP-1 agonists compared to an active comparator. Five
studies (Gill 2010, Bunck 2009, Davis 2007, Derosa
2010, and DeFronzo 2010) [22,26,27,29,31] could not be
included in these meta-analyses due to the relevant data
not being reported. The data for Bergenstal 2010 [37]
was estimated from the graph.
GLP-1 agonists versus insulin
As with the results for changes in HbA1c, there was
highly significant heterogeneity when combining the two
trials [28,33] comparing BIAsp 30 twice daily and exena-
tide. Bergenstal 2009 reported significantly fewer
patients achieving a target HbA1c level of ≤ 7% with
exenatide compared to BIAsp 30 twice daily group (20%
vs. 37%, p = 0.004), while Nauck 2007 reported a higher
number of patients achieving this target with exenatide
(32% vs. 24%; p = 0.05).
Heine 2005 [32] found no significant difference
between exenatide and glargine (46% vs. 48%), and Rus-
sell Jones 2009 [35] (LEAD-5) found no significant dif-
ference between liraglutide 1.8 mg daily and glargine
(53% versus 46%). Diamant 2010 [34] found that exena-
tide 2 mg once weekly led to a slightly greater
proportion of patients achieving this target than with
insulin glargine (60% vs. 48%; p = 0.03)
GLP-1 agonists versus sulphonylureas
There was no significant difference between liraglutide
1.2 mg or 1.8 mg daily and glimepiride (35% or 42% ver-
sus 36%) [36].
GLP-1 agonists versus pioglitazone
Bergenstal 2010 [37] found that exenatide 2 mg once
weekly led to significantly higher number of patients
achieving HbA1c level of ≤7% than with pioglitazone 45
mg daily (59% vs. 31%).
GLP-1 agonists versus sitagliptin
Bergenstal 2010 [37] found that significantly greater
number of patients achieved a target HbA1c level of
≤7% with exenatide 2 mg once weekly than with sita-
gliptin 100 mg daily (59% vs. 44%; p = 0.008). Russell
Jones 2009 [35] (LEAD-5) found that the proportion of
participants achieving this target was significantly higher
with liraglutide 1.2 mg daily and sitagliptin (56% vs.
22%).
GLP-1 agonists versus rosiglitazone
The proportion of participants achieving HbA1c level of
≤7% was significantly higher with liraglutide 1.2 mg
daily compared to rosiglitazone 4 mg daily (35% vs.
22%) [39].
Table 2 Quality of included trials (Continued)
Kaku 2010
[18]
Unclear Unclear Yes,
Double
blind
Yes Lir 0.6/Lir 0.9/P: 94.3/95.5/84.1 Yes Yes Unclear
Pratley 2010
[38]
Yes Yes No,
Open
label
Yes Lir 1.2/Lir 1.8/Sita: 75.1/86.4/88.6 Yes Yes Yes
Marre 2009
(LEAD-1) [39]
Unclear Unclear Yes,
Double
blind
Yes Lir 1.2/Lir 1.8/Rosi/P:
86.0/91.0/83.6/72.8
Yes Yes Yes
Nauck 2009
(LEAD-2) [36]
Yes Yes Yes,
Double
blind
Yes Lir 1.2/Lir 1.8/Glim/P:
82.1/78.9/86.8/61.2
Yes Yes Yes
Zinman
2009 (LEAD-
4) [44]
Yes Yes Yes,
Double
blind
Yes Lir 1.2/Lir 1.8/P: 86.0/74.7/68.4 Yes Yes Yes
Russell-Jones
2009 (LEAD-
5) [35]
Yes Yes Unclear Yes Lir 1.8/Glar/P: 90.0/94.4/84.2 Yes Yes Yes
Buse 2009
(LEAD-6) [40]
Unclear Yes No,
Open
label
Yes Lir 1.8/Exe: 86.7/81.0 Yes Yes Yes
Nauck 2009
[24]
Yes Yes Yes,
Double
blind
Yes Tas 10 mg QW/Tas 20 mg QW/
Tas 20 mg every two weeks/P:
91.8/88.0/93.9/95.9
Yes Yes Yes
Ratner 2010
[25]
Yes Unclear Yes,
Double
blind
Yes Tas 20 mg QW/Tas 30 mg QW/
Tas 40 mg QW: 90.6/81.8/81.3/
96.9
Yes Yes No
Albi: Albiglutide; Exe: Exenatide; Exe lar: long acting exenatide; Lir: Liraglutide; Tas: Taspoglutide; BIAsp: Biphasic insulin aspart; Glar: Insulin glargine; Ins: Insulin;
Glib: Glibenclamide; Glim: Glimepiride; Pio: Pioglitazone; Rosi: Rosiglitazone; Sita: Sitagliptin; P: Placebo; BID: Twice daily; QD: Once daily; QW: Once weekly; HEELA:
Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin; LEAD: Liraglutide Effect and Action in Diabetes
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Page 13 of 26GLP-1 agonists versus GLP-1 agonists
Drucker 2008 [41] reported that exenatide 2 mg weekly
was superior to the 10 µg twice daily dose (77% vs. 61%;
p = 0.004), and liraglutide 1.8 mg daily was significantly
better than exenatide 10 μg twice daily (54% vs. 43%;
p=0 . 0 2 ) .T h e r ew a sn os i g n i f icant difference between
the liraglutide 1.2 mg and 1.8 mg dose.
Body weight
As shown in Figure 6, mean weight losses with GLP-1
agonists ranged from 0.7 to 1.3 kg. Several trials reported
that weight loss occurred in patients not experiencing
nausea [21,32,35,36,41,42]. All GLP-1 agonists caused
greater weight loss compared with placebo, apart from
the Marre 2009 [39] (LEAD-1) trial, where the liraglutide
1.2 mg arm gained 0.3 kg, and the placebo arm lost 0.1
kg; the differences were not statistically significant.
A ss h o w ni nF i g u r e7 ,g r e a t e rr e l a t i v ew e i g h tl o s s
occurred in trials of GLP-1 agonists against active com-
parators than with trials against placebo, as all of the
non GLP-1 active comparators except sitagliptin tended
to cause weight gain.
Figure 2 Change in HbA1c (%): GLP-1agonists versus placebo.
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Page 14 of 26GLP-1 agonists versus insulin
Patients in the exenatide versus insulin trials lost
between 1.9 and 4.2 kg of weight, whereas patients in
the insulin groups gained between 0.5 and 4.1 kg of
weight. The meta-analysis showed a significant differ-
ence in favour of exenatide for BIAsp30 insulin and
insulin glargine, and a non-significant loss against a
mixture of insulin regimens. Diamant 2010 [34] showed
Figure 3 Change in HbA1c (%): GLP-1 agonists versus active comparators.
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Page 15 of 26a significantly greater reduction in weight with exenatide
2 mg once weekly and an increase with insulin glargine
(-2.6 vs. +1.4 kg; p < 0.00001). In Russell-Jones 2009
[35] (LEAD-5), liraglutide was found to cause significant
weight reduction (-1.8 kg) compared to an increase
(+1.6 kg) with insulin glargine.
GLP-1 agonists versus sulphonylureas
Exenatide was also found to cause weight loss compared
to gains with glibenclamide (-8 kg vs. +4.30 kg; p <
0.001) in Derosa 2010 [27]. In Nauck 2009 [36] (LEAD-
2), liraglutide 1.2 mg and 1.8 mg showed significant
weight loss compared to glimepiride (-2.6 to -2.8 kg vs.
+1 kg; p < 00001).
GLP-1 agonists versus pioglitazone
Exenatide 2 mg once weekly led to weight loss whereas
pioglitazone 45 mg daily caused weight gain (-2.3 vs.
+2.8 kg; p < 0.00001) [37].
GLP-1 agonists versus sitagliptin
In Bergenstal 2010 [37], exenatide led to a significantly
greater weight loss with exenatide 2 mg once weekly than
with sitagliptin 100 mg daily (-2.3 vs. -0.8 kg; p = 0.0009).
GLP-1 agonists versus rosiglitazone
In DeFronzo 2010 [22], exenatide was found to cause
weight loss, compared to a gain with rosiglitazone 4 mg
twice daily (-2.8 kg vs. +1.5 kg, p < 0.001). Similarly in
Marre 2009 [39], liraglutide 1.2 mg and 1.8 mg led to
significant weight loss compared to rosiglitazone 4 mg
once daily (-0.2 and +0.3 kg vs. +2.1 kg, p < 0.0001).
GLP-1 agonists versus GLP-1 agonists
Drucker 2008 [41] compared twice daily exenatide ver-
sus once weekly exenatide, and found no difference in
weight loss or the proportions losing weight (76% with
exenatide once weekly versus 79% with exenatide twice
daily). Weight decreased in participants who reported
no episodes of nausea throughout the study (70%). In
Buse 2009 [40] the amount of weight loss was similar
with exenatide and liraglutide (-2.87 kg vs. -3.24 kg), as
was the proportion of participants who lost weight (78%
v s .7 6 % ) .T h e1 . 8m gd o s eo fl i r a g l u t i d eg a v es l i g h t l y
greater weight loss than the 1.2 mg dose, with overall
mean difference of 0.48 kg (95% CI 0.16 to 0.80).
Fasting and postprandial plasma glucose (FPG and PPG)
As shown in additional file 1 all GLP-1 agonists signifi-
cantly reduced FPG compared with placebo, partly
because most of the placebo groups showed a small
increase in FPG.
The overall difference between trials comparing exe-
natide 10 μg twice daily and insulin glargine in FPG was
1.37 mmol/l [95% CI 1.01 to 1.73] (with a heterogeneity
of I
2 = 0%) in favour of glargine [29,30,32]. However,
t h et r i a lo fl i r a g l u t i d e1 . 8m gd a i l yv e r s u sg l a r g i n e
showed a non-significant difference of 0.24 mmol/l (95%
CI -0.34 to 0.82) in favour of liraglutide [35].
Liraglutide reduced FPG significantly more than exe-
natide 10 μg twice daily by 1.01 mmol/l (95% CI 0.46 to
1.56) [40]. Long acting exenatide (2 mg weekly) caused
a significantly greater reduction of 0.90 mmol/l (95% CI
0.35 to 1.45) in FPG compared to exenatide 10 μgt w i c e
daily. Bergenstal 2010 [37] found a significant difference
in favour of exenatide 2 mg once weekly compared with
sitagliptin 100 mg daily (-0.90 mmol/l, 95% CI -1.50,
-0.30; p = 0.0038) but a non-significant difference
against pioglitazone 45 mg daily (-0.30 mmol/l, 95% CI
-0.90 to 0.30; p = 0.33).
In the studies that reported on PPG, the values were
derived differently in each study. PPG was lower in all
GLP-1 groups compared to placebo, and there was sig-
nificantly less variability in results from self monitoring
blood glucose (SMBG).
In one head to head trial [40], exenatide led to a greater
reduction in PPG increment than liraglutide after break-
fast and dinner (treatment differences were: breakfast
1.33 mmol/L, 95% CI: 0.80 to 1.86, p < 0.0001; dinner
1.01 mmol/L, 95% CI: 0.44 to 1.57, p = 0.0005) however
the difference was not significant after lunch, which fits
with the time of administration [40]. Exenatide 10 µg
twice daily was superior to the once weekly 2 mg regimen
in controlling PPG. Exenatide 2 mg once weekly showed
significantly greater reduction in PPG than did sitagliptin
(p < 0.05) but not compared to pioglitazone [37]. Exena-
tide 2 mg once weekly led to greater reduction in post
prandial glucose excursions after morning (p = 0.001)
and evening (p = 0.033) meals than insulin glargine [34].
Blood pressure
In all but one trial [18], GLP-1 agonists led to reduc-
tions in SBP of a few mmHg. In most studies, the differ-
ences in reduction in DBP with GLP-1 s were not
significant (see additional file 1).
Lipid profile
No significant changes were seen in the lipid profiles of
the participants treated with either albiglutide or placebo.
Five exenatide trials [20,22,30,41,43] reported results for
lipid profiles. No significant reductions in lipid para-
meters were seen in comparison with either placebo or
insulin. Exenatide 10 μg twice daily however showed sig-
nificant reduction (-0.13 vs. +0.44; p < 0.001) in total
cholesterol (TC) and LDL (-0.05 vs. +0.33; p = 0.008) in
comparison with rosiglitazone [22]. Once-weekly long
acting exenatide led to greater reduction in TC (-0.31 vs.
-0.10) and LDL (-0.13 vs. +0.03) than twice daily exena-
tide [41]. Bergenstal 2010 [37] found that all drugs
improved HDL levels, but only pioglitazone reduced tri-
glycerides significantly. There was a reduction in the
total cholesterol level and LDL with exenatide 2 mg once
weekly, but an increase with pioglitazone and sitagliptin.
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Page 16 of 26The differences were not significant. Diamant 2010 [34]
found that exenatide 2 mg once weekly led to slightly
greater reduction in TC and LDL than with glargine
(-0.12 vs. -0.04 mmol/l TC; -0.05 vs. +0.04 mmol/l LDL).
There was no difference in triglyceride levels.
Only three liraglutide trials [38,40,44] reported lipid
profiles in detail and one [18] reported briefly. In
LEAD-4 [44], there was significantly more reduction in
triglycerides, TC and LDL cholesterol with 1.2 mg daily
liraglutide (but, oddly, not with 1.8 mg liraglutide) than
Figure 4 Percentage of patients achieving HbA1c ≤7%:GLP-1 agonists versus placebo.
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Page 17 of 26with placebo. There were no significant differences in
the lipid profiles between liraglutide 1.8 mg and sitaglip-
tin, apart from a modest decrease -0.16 mmol/l (95% CI
-0.30 to -0.01) in total cholesterol, in favour of
liraglutide [38]. Kaku 2010 [18] compared liraglutide
0.6 mg and 0.9 mg and reported no significant changes
in lipid profiles. In the LEAD 6 trial [40], liraglutide 1.8
mg led to a significantly greater reduction in triglycer-
ides (TG) -0·18 (95% CI -0·37 to 0·00) than exenatide 10
μg twice daily. There were no significant differences in
any other lipid parameters. Taspoglutide caused a dose-
related decline in TG levels and a small decrease in TC
levels. None of the other lipid parameters showed any
consistent changes.
Beta cell function
All GLP-1 agonists led to significant improvements in
beta-cell function, but these did not persist once users
stopped the drug [29]. The improvement with GLP-1
agonists was better than with glargine and rosiglitazone,
but no different from glimepiride [36]. There was no
difference between liraglutide and exenatide [40].
Treatment satisfaction/Quality of life
Only two trials [34,37] reported quality of life using
weight related quality of life or Impact of Weight on
Quality of Life (IWQOL) and EuroQoL questionnaires.
Also both studies used the Diabetes Treatment Satisfac-
tion Questionnaire (DTSQ) to assess the overall treat-
ment satisfaction. Overall treatment satisfaction was also
reported by one exenatide [41] and two liraglutide trials
[38,40]. All three studies used the DTSQ. In the two lir-
aglutide trials, only subgroups of patients completed the
questionnaires.
Bergenstal 2010 [37] found that all the five parameters
of weight-related QOL and IWQOL total score signifi-
cantly improved with exenatide 2 mg once weekly
(IWQOL total score 5.15, 95% CI 3.11 to 7.19) and sita-
gliptin (4.56, 95% CI 2.56 to 6.57) but not with pioglita-
zone (1.20, 95% CI -0.87 to 3.28). The improvement in
IWQOL total score with exenatide was consistent with
differences in body weight changes. Overall treatment
satisfaction was also higher with exenatide 2 mg once
weekly than with sitagliptin (3.96 vs. 2.35; difference
1.61, 95% CI 0.07 to 3.16; p = 0.0406). Diamant 2010
[34] reported significant improvements for one of the
IWQOL-Lite domains and one EQ-5D dimension with
exenatide 2 mg once weekly compared with insulin glar-
gine, but no data were given.
There was no significant difference in treatment satis-
faction between the exenatide once a week and the exe-
natide twice daily groups [changes observed using
DTSQ; exenatide once weekly 0.84 vs. exenatide twice
daily 0.64; p = 0.09] [41]. Overall satisfaction was higher
with liraglutide 1.8 mg than with exenatide 10 μgt w i c e
daily, but while the difference was statistically significant
(liraglutide 1.8 mg 15.18 SE 0.58 vs. exenatide 13.30 SE
0.58; estimated treatment difference 1.89 (95% CI 0.85
Figure 5 Percentage of patients achieving HbA1c ≤7% GLP-1
agonists versus active comparators.
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Page 18 of 26to 2.92); p = 0.0004) the difference of less than two
points was small on the 36-point scale [40]. Similarly,
there was little difference between liraglutide and sita-
gliptin (DTSQ; liraglutide 1.2 mg vs. sitagliptin p = NS;
liraglutide 1.8 mg vs. sitagliptin change from baseline
1.39 on the 36 point scale (95% CI 0.13 to 2.64),
p = 0.03), implying that patients did not find that having
to inject liraglutide was a problem [38].
Hypoglycaemia
The definition of hypoglycaemia was given in most stu-
dies. Minor hypoglycaemia was defined as an episode
Figure 6 Weight changes (kg): GLP-1 agonists versus placebo.
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Page 19 of 26that could be self-treated, while those needing third
party assistance or medical interventions were cate-
gorised as major. Results showing the incidence of hypo-
glycaemia are shown in additional file 2.
The incidence of minor hypoglycaemia was signifi-
cantly greater in trials where patients were taking exena-
tide in combination with sulphonylureas [20,21,43,45]
compared to those not taking sulphonylureas. Minor
Figure 7 Weight changes (kg): GLP-1 agonists versus active comparators.
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Page 20 of 26hypoglycaemia was higher with liraglutide than rosiglita-
zone in Marre 2009 [39] (LEAD -1) (where treatment
included sulphonylureas in both arms), and in Nauck,
2009 [36] (LEAD-2) it was higher with glimepiride than
liraglutide (17% vs. 3%).
The incidence of major hypoglycaemia was low with
GLP-1 s. Davis 2009 [30] reported three episodes in one
patient taking exenatide in combination with a sulpho-
nylurea, and none in the insulin group. Bunck 2009 [29]
reported more overall hypoglycaemia with glargine
(24.2% vs. 8.3%) than exenatide, but there was no severe
hypoglycaemia in either group. In the Davies 2009 [30]
and Heine 2005 [32] trials, the rates of overall and
severe hypoglycaemia were similar, but in the latter trial,
the rate of nocturnal hypoglycaemia was higher with
glargine than with exenatide. Diamant 2010 [34]
reported a greater number of patients with minor hypo-
glycaemia in the insulin glargine group than the exena-
tide 2 mg once weekly group (26 vs. 8%). Two patients
(one taking metformin only and the other taking met-
formin plus sulphonylurea) in the glargine group and
one in the exenatide 2 mg once weekly group (taking
metformin only) had major hypoglycaemia.
In the Marre 2009 [39] (LEAD 1) trial, one patient
taking liraglutide 1.8 mg and glimepiride had major
hypoglycaemia, and this was considered to be related to
glimepiride. In Russell-Jones, 2009 [35] (LEAD 5), five
patients had major hypoglycaemic events in the liraglu-
tide group, and in Buse 2009 [40] (LEAD 6) patients in
the exenatide group reported two episodes of major
hypoglycaemia, whereas none were found in the liraglu-
tide group. Pratley 2010 [38] reported that one patient
on 1·2 mg liraglutide had a major hypoglycaemic epi-
sode, but none on the 1.8 mg dose or on sitagliptin.
The other liraglutide trials reported no severe hypogly-
caemia in any group [18,36,44].
There were no significant differences in the incidence
of hypoglycaemia in trials comparing albiglutide or tas-
poglutide and placebo.
Adverse events
Details of adverse events are shown in additional file 2.
The most commonly reported adverse events were nau-
sea, vomiting and diarrhoea, and withdrawals from the
trials were mostly because of these events. In head to
head trials comparing one GLP-1 agonist against
another (exenatide vs. liraglutide and exenatide twice
daily vs. exenatide once weekly) there were no signifi-
cant differences in initial frequency [40,41], but nausea
was less persistent with liraglutide compared to exena-
tide [40]. Nausea and vomiting were less with once
weekly exenatide compared with twice daily exenatide
[41]. Most studies stated that gastrointestinal effects
were worst at the beginning and tended to be reduced
over the course of the study. There were reports of mild
to moderate injection site reactions, which did not lead
to any discontinuation.
Only one case of pancreatitis was reported with exe-
natide [29] however it resolved after stopping the medi-
cation. Similarly, one case of acute pancreatitis was seen
with 1.2 mg liraglutide [36] and the patient withdrew
from the study. Another patient taking liraglutide 1.8
mg developed chronic pancreatitis; however the investi-
gators considered that it was unrelated to the drug [40].
Discussion
This systematic review and meta-analysis included
twenty eight randomised controlled trials and compared
four different GLP-1 agonists against placebo and a
number of active comparators. The comparisons were:
albiglutide and taspoglutide against placebo; exenatide
against placebo, insulin, glibenclamide, rosiglitazone;
exenatide twice daily against exenatide once weekly; exe-
natide once weekly against sitagliptin and pioglitazone;
and liraglutide against placebo, exenatide, glimepiride,
rosiglitazone, sitagliptin and insulin glargine. All but one
of the trials were sponsored by the manufacturers, and
where details are given, the manufacturers were involved
in, or carried out, data analysis.
Summary of principal findings
The results showed that GLP-1 agonists are effective in
improving glycaemic control and promoting weight loss,
with a low risk of hypoglycaemia, and can be an alterna-
tive to immediate insulin in patients failing on combined
oral glucose lowering agents.
HbA1c
Results varied against active comparators. Liraglutide 1.8
mg daily was superior to glargine, rosiglitazone 4 mg
daily, sitagliptin 100 mg daily and exenatide 10 μgt w i c e
daily. Exenatide 10 μg twice daily was equivalent to both
insulin and rosiglitazone 4 mg twice daily, taking differ-
ences in HbA1c of less than 0.5% as being not clinically
significant. Long acting exenatide (2 mg weekly) was
superior to exenatide 10 μg twice daily, glargine, sita-
gliptin and pioglitazone 45 mg daily.
Weight loss
Exenatide and liraglutide caused greater weight loss
than all active comparators, most of which led to weight
gain. Weight loss was independent of nausea. A study
that followed trial patients for longer has shown that
temporal patterns of weight loss can vary amongst
patients. [46]
Hypoglycaemia and adverse events
The incidence of major hypoglycaemia was very low (in
absolute terms) in patients taking GLP-1 agonists, and
the incidence of minor hypoglycaemia was low (under
10%) compared to most other glucose lowering agents
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when GLP-1 analogues were used in combination with
sulphonylureas, in which cases it was probably due to
those rather than the GLP1 agonist. The most com-
monly reported adverse events with GLP-1 agonists
were gastrointestinal, and included nausea, vomiting and
diarrhoea. These adverse events were worst at the begin-
ning and reduced over the course of therapy. Most
patients did not get nausea while taking a GLP-1
agonist.
Strengths and Limitations
This review carried out a systematic search to identify
all the relevant papers on the effectiveness of GLP-1
agonists in patients with type 2 diabetes who are inade-
quately controlled with oral hypoglycaemic agents. All
the included studies are randomised controlled trials
comparing GLP-1 agonists against a placebo, an active
comparator or other GLP-1 agonists. We have only
included trials that have used a clinically relevant dose
of a GLP-1 agonist. We excluded trials of GLP-1 analo-
gues against placebo in patients on no other glucose
lowering drug, because in practice, older cheaper drugs
with long safety records, such as metformin, should be
used first. Also, we have only included clinically relevant
comparators, and excluded patients who were naïve to
therapy or who were treated with a GLP-1 agonist as
monotherapy. Wherever possible, the data were meta-
analysed. We have separately analysed GLP-1 agonists
versus placebo, and GLP-1 agonists versus active
comparators.
This review includes searches up to July 2010, and
hence includes the newest GLP-1 agonists, such as tas-
poglutide, albiglutide and long acting exenatide.
Limitations to our review
We did not include data from observational studies in
the main results. Some of these studies have suggested
that results in routine care are not as good as in the
RCTs. For example, Loh and Clement found no signifi-
cant improvement in HbA1c at two years, and that
most of the weight lost was regained [47]. However a
subgroup did well on both parameters. Observational
studies may be useful for identifying those patients most
likely to do well on the GLP-1 agonists. However, most
studies from routine care are available only as confer-
ence abstracts.
We included only those doses which were licensed, or
in the case of unlicensed drugs, we included doses
which seemed from the trial results, or from the
authors’ comments, to be the ones likely to be used in
clinical practice.
In the meta-analyses, we grouped trials comparing
GLP-1 agonists versus comparators, irrespective of the
co-medications used (as long as the co-medications
were the same across arms). This assumed that the
effect size of GLP-1 agonists against comparators does
not depend on whether the GLP-1 agonists are used as
a second drug or a third drug. We investigated the effect
of co-medications in the liraglutide trials, some of which
used liraglutide in dual and some in triple therapy. The
proportion of patients who had received previous dual
therapy ranged from zero to 84%. However, there was
no systematic difference in reductions in HbA1c
between the dual and triple therapy trials. There were
also, as mentioned above, uncertainties or lack of data
on which medications patients had had before entry.
Most limitations reflected gaps in the evidence,
including the following.
Head to head comparisons of GLP-1 agonists
T h e r ei sc u r r e n t l yo n l yo n et r i a lc o m p a r i n go n eG L P - 1
agonist against another (liraglutide versus exenatide),
and no firm conclusions can be made on the relative
effectiveness of different GLP-1 agonists.
Exenatide 2 mg weekly was superior to exenatide 10
µg twice daily with respect to HbA1c. In the head-to-
head comparison of exenatide 10 μg twice daily and lira-
glutide, liraglutide was superior to exenatide. This trial
was sponsored by the manufacturer of liraglutide, but
the findings appear plausible and in keeping with the
pharmacodynamics of the two drugs, with liraglutide
having a more prolonged action with less of a “peak and
trough” effect. The trial of weekly exenatide versus twice
daily exenatide showed that the weekly version reduced
H b A 1 cb y0 . 4 %m o r et h a nt h et w i c ed a i l yo n e ,s oa n
indirect comparison would suggest that weekly exena-
tide might be more potent than daily liraglutide. Hence,
t h ef u t u r eo ft h eG L P - 1a g o nists would appear to be as
a medication given weekly, or even every two weeks.
T h eo n l ya d v a n t a g eo ft h et w i c ed a i l yf o r m u l a t i o no f
exenatide compared with the weekly one, was that it
gave better control of PPG. There has been concern
that post-prandial excursions might be an independent
(of overall control) risk factor for complications, but this
is unproven [48]. Diamant 2010 [34] showed better con-
trol of PPG with exenatide once weekly than with
glargine.
Our meta-analysis showed that there was little advan-
tage of the 1.8 mg dose over the 1.2 mg dose of liraglu-
tide, with no difference in HbA1c, but slightly greater
weight loss.
At present, any comparison amongst GLP-1 agonists
would have to be done by indirect comparison, which
c o u l do n l yb ed o n eu s i n gs t u d ies where co-medications
were the same, and where there was a common com-
parator. Indirect comparisons are not as good as head
to head trials, but are sometimes the best that can be
done if such trials are not available, and are hence sug-
gested by the National Institute for Health and Clinical
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appraisal June 2008 [49].
Lack of trials against, or in combination with, insulin
Only four exenatide trials and one liraglutide trial made
comparisons against insulin glargine, the most com-
monly used basal insulin in the UK. There have been no
trials against NPH insulin, which is more cost-effective
in type 2 diabetes than the long-acting analogues [50].
There were no trials of combinations of basal insulin
and GLP-1 agonists. Given their different actions, such
combinations seem logical, but are currently unlicensed.
Observational studies suggest their safety and efficacy
[51].
Lack of trials against pioglitazone
T h e r ei so n l yo n et r i a lo faG L P - 1a g o n i s t sa g a i n s tp i o -
glitazone, which because of its better cardiovascular risk
profile than rosiglitazone, is now preferable [50].
Length of trials
Only two studies lasted 52 weeks - so there is insuffi-
cient evidence regarding long-term outcomes. Two stu-
dies lasted only 8 weeks. The studies included in this
review were not long enough to entirely remove con-
cerns about pancreatitis and renal failure [52-54] with
exenatide or pancreatitis and thyroid carcinoma [55]
with liraglutide. There have been reports of pancreatitis
with exenatide and liraglutide, but it is difficult to prove
if the drugs are responsible because the incidence of
pancreatitis is increased in type 2 diabetes [56].
Type 2 diabetes is usually a progressive disease, and
trials to date have not been long enough to tell us for
how long the GLP-1 agonists would be effective. Short
duration of the trials do not provide data on cardiovas-
cular outcomes [57].
Losses to follow-up
Many of our inclusions had one or more arms with
losses to follow up of > 20%. Ideally, trials with an attri-
tion rate of between 5 and 20% are acceptable, but
greater proportions may pose a threat to validity [58,59].
Doses of comparators used in trials
In the LEAD-1 trial of liraglutide against rosiglitazone,
t h e4m gd a i l yd o s ew a su s e d .T h em a n u f a c t u r e r ,N o v o
Nordisk, explained that this was because the trial was
d o n ei nan u m b e ro fc o u n t r i e s ,i ns o m eo fw h i c ht h e8
mg dose is not licensed. It is possible that using the larger
dose might not have made much difference. There is one
trial comparing the two doses, by Fonseca et al, in which
the HbA1c gain from the larger dose was only 0.22% [60].
In the trial by Pratley et al, 22% of patients achieved
an HbAlc level ≤7% on sitagliptin [38]. In LEAD 1, 22%
reached the same target on 4 mg daily rosiglitazone
[39]. Hence, it appears worth trying both of those agents
before a GLP-1 agonist, because almost a quarter of
patients will achieve good control, at least in the short
term.
Previous reviews
There have been several good quality reviews, including
those by Monami and colleagues [11], Barnett [10],
Amori and colleagues [9], and Norris and colleagues
[12], and a health technology assessment (HTA) report
[50]. However, some include all comparators in all trials
(i.e. not all are relevant to clinical practice), and none
include trials published up to July 2010. Also, some
reviews did not include all the GLP-1 agonists.
Beta-cell function
As beta- cell capacity declines, some of the GLP-1 ago-
nist effects would be lost, but others (such as satiety)
might persist. A technology assessment report [50]
assumed that exenatide would be used instead of insulin
for, on average, five years. This is based on its 1% effect
on HbA1c, and the expected rise over time of about
0.2% a year due to declining beta cell function. However,
data are lacking on whether the underlying decline
would be slowed by GLP-1 agonists.
The main interest, or hope, in some of the studies has
been whether the GLP-1 agonists might preserve or ever
foster recovery of beta-cell function. If they did, this
would be a major breakthrough in what is currently a
progressive disease. As reported above, in short-term
trials the effect on beta-cell function is lost after the
GLP-1 agonist is stopped. However, a recent report,
available in abstract only, suggests that after three years
of exenatide, the beta-cell effect may persist [61].
If GLP-1 analogues do enhance beta-cell survival and
stimulate beta-cell growth, they may provide a means to
preserve or restore functional beta-cell mass in indivi-
duals with type 2 diabetes. More details of the effect on
beta-cell function are available in a good recent review
by Vilsboll, in which she concluded that longer trials
were necessary [62].
Where do GLP-1 agonists fit into the clinical pathway?
The disadvantages of GLP-1 agonists, compared to other
options in dual therapy, are the need to inject, the cost,
and the nausea. It does not seem appropriate to start an
expensive injectable agent before inexpensive oral drugs
have been tried. So the place for the GLP-1 agonists is
likely to be in triple therapy, in conjunction with two
oral drugs. Their advantage, compared to sulphonylureas
and glitazones, is weight loss. This advantage is less in
comparison with the gliptins, which are weight neutral.
In patients whose control is inadequate on two oral
drugs (usually metformin and a sulphonylurea), the
options are: a third oral drug (such as a gliptin or a gli-
tazone); a GLP-1 agonist; or starting insulin. There are
no trials of GLP-1 agonists against gliptins or glitazones
in this triple therapy situation. There are only two fully-
published trials of GLP-1 agonists against a gliptin, and
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appeared more effective than sitagliptin as second drug.
However, in routine care, one would try an inexpensive
oral drug before an expensive injectable; so the key
question is the extent to which liraglutide would
improve HbA1c in patients in whom a gliptin had been
tried and had failed. In that situation the comparator
would be insulin, and following the 4T study [63], the
first choice of insulin would be a once daily basal.
In the UK, the NICE guideline suggests that the GLP-
1 analogues (at the time, only exenatide was available)
should be used as third line agents [3]. NICE also sug-
gest “stopping rules” [3,64] which include a reduction
in HbA1c of at least 1%, and 3% weight loss by six
months. However, there are different patterns of weight
loss. In a pooled post-hoc analysis, Kendall and collea-
gues reported that some patients treated with exenatide
lost weight quickly (in the first 3 months), while others
lost weight more slowly over a longer period, but both
groups ending up with about 5% body weight loss by
two years. About 20% did not lose weight, and while
this group also achieved initial improvement in HbA1c,
that was rising again in the second year [46]. Similarly,
Klonoff and colleagues [65] reported that weight loss
continued to 156 weeks, in a pooled follow-up of 415 of
patients from three exenatide trials (who may have over-
lapped with those in the Kendall paper) [46].
The trials against insulin showed weight gain with
insulin and weight loss with exenatide and liraglutide.
Previous studies have noted that in routine care (as
opposed to in trials), treatment with insulin often fails
to achieve good control [6], especially in the most over-
weight [66]. It may be that the benefits of GLP-1 ago-
nists, compared to starting insulin immediately, will be
relatively greater as BMI increases.
On-going trials
There is a need for trials of GLP-1 agonists against insu-
lin in patients who do not achieve adequate control on
triple oral therapy, and a need for more trials of combi-
nation therapy, with both a GLP-1 agonist and basal
insulin, which seems a logical combination in view of
their modes of action.
A large number of trials are in progress or planned,
involving not only the four GLP-1 agonists described in
this review, but newer ones such as lixisenatide and
LY2189265. The trials include:
￿ Head to head comparisons of individual GLP-1
agonists, such as long-acting (once weekly) exenatide
versus liraglutide and of weekly taspoglutide versus
twice daily exenatide (which may become an obso-
lescent comparison once long-acting exenatide is
licensed).
￿ Trials of longer intervals between doses, such as a
trial of exenatide given once a month.
￿ Comparisons of GLP-1 agonists versus long-acting
insulins.
￿ Comparisons of GLP-1 agonists with gliptins and
glitazones.
￿ Trials of combination therapy of GLP-1 agonists
with insulins.
Conclusions
GLP-1 agonists are effective in improving glycaemic
control when added to dual therapy, and at least in the
short term, can be an alternative to starting insulin. The
incidence of hypoglycaemia is low, because of their
glucose dependent action. They also cause weight reduc-
tion, in contrast to the weight gain seen with sulphony-
lureas, the glitazones and insulin, and the weight neutral
effects of the gliptins. How long they would work for in
a progressive disease is not yet known. They are a useful
addition to the therapeutic armamentarium in type 2
diabetes.
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